The Institute for Liver Health
Welcome,         Profile    Billing    Logout  
 0 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sachdeva, Yessica
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
COMET-PACE, NCT05124210 / 2021-003717-18: Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

Terminated
2
8
US
Sotrovimab
GlaxoSmithKline, Vir Biotechnology, Inc.
COVID-19
06/23
06/23
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
275
US, RoW
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
179
US, RoW
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
01/25
05/25
NCT06074562: A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Recruiting
2
410
Europe, Japan, US, RoW
LY3556050, Placebo
Eli Lilly and Company
Diabetic Peripheral Neuropathy
07/25
07/25
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25

Download Options